The "gold-standard" clinical trial found that hydroxychloroquine could not prevent COVID-19 any better than a sugar pill.
WEDNESDAY, June 3, 2020 (HealthDay News) -- Hydroxychloroquine, the malaria drug touted and reportedly used by President Donald Trump as a preventative for COVID-19, appears not to have lived up to its hype, a new study shows.
Unlike some prior studies, this new trial was a "gold standard" prospective, randomized clinical trial. It found that hydroxychloroquine could not prevent COVID-19 any better than a sugar pill.
Worse, 40% of those taking hydroxychloroquine developed side effects including nausea, upset stomach or diarrhea. Fortunately, no serious side effects or heart problems occurred in the study, the researchers noted. An uptick in risk for potentially dangerous heart rhythm abnormalities had been noted in prior studies in which COVID-19 patients received hydroxychloroquine as a treatment.